### HIVPA CONFERENCE

AGENDA FOR SEPTEMBER 2022 CONFERENCE

### **RESEARCH**

COLLABORATIVE HIV-2
RESEARCH FROM LONDON
CENTRES


### **HIVPA NEWS**

LATEST UPDATES FROM THE COMMITTEE



**HIV Pharmacy Association** 





hivpaoffice@gmail.com

### **HIVPA News**

### Hello and welcome to the Summer HIVPA Bulletin!

I write this on the heels of my first AIDS 2022 (only virtually, unfortunately). The activism and community spirit on show was a pleasant surprise and I'm inspired to raise the volume of the community's voice in my local practice. For many of us the monkeypox outbreak dominates our discussions and time, however life and routine care must go on! The speciality has forged ahead and as always our teams are an integral part of that mobilisation despite the inevitable pressure this places on our practice.

As always please continue to shout about the amazing work you and your teams do and the Bulletin welcomes all contributions, no matter how big or small.

Yemi Daramola, HIVPA Bulletin Lead

### **HIVPA Conference!**

The HIVPA conference will return this September, with a one day event on the 3rd of September 2022 at events which replaced the HIVPA study days are the Pullman Hotel, London Kings Cross. The proposed available for members to watch online. Links can be agenda can be found below with further information on the HIVPA website.

https://hivpa.org/hivpa-conference-2021/

### Monkeypox resources from BASHH

The UK Health Security Agency (UKHSA) are leading the response to the confirmed cases of Monkeypox and BASHH are working closely with them and other sector representatives. Please find below links to UKHSA, CAS and also operational documents for clinics to use

https://www.bashh.org/news/monkeypox-resources/

### **BHIVA** rapid guidance on monkeypox virus

BHIVA have collated rapid guidance on the impact of HIV on MPV and information on vaccine efficacy and treatment.

https://www.bhiva.org/BHIVA-rapid-guidance-on-monkeypox-virus

### **HIVPA Virtual Education Events**

A reminder that recordings of the virtual educational found on the HIVPA eHIVe site. Further content will be released later in the year.



https://ehive.hivpa.org/training-modules/

### **BHIVA Spring Conference webcasts**

For those who were unable to attend the BHIVA Spring conference this year, some of the presentations are available online here.

https://www.bhiva.org/AnnualConference2022Presentations

### **New HIVPA PILs & Resources**

New HIVPA Patient information leaflets and resources to support the 2022 changes to the national ARV contract are now available on the HIVPA website

https://hivpa.org/patient-information-leaflets-pils/

### **Thanks to our Sponsors**

The HIVPA committee would like extend a special thanks to all of our sponsors for their continued support, especially over the past few years. The support of our sponsors is essential to much of the work carried out by HIVPA including the return of the conference. Thank you.

**Gilead Sciences** 

Mylan

**Merck Sharp & Dohme Limited** 

**ViiV Healthcare** 

**Dr Reddy's Laboratories** 

### **HIVPA Conference 2022 Agenda**

### **HIVPA Annual Conference**

Saturday 3<sup>rd</sup> September 2022 Location: The Pullman Hotel, London

#### **Provisional programme**

09.00-09.20 Arrival and registration
 09.20-09.30 Conference chair introduction (10 mins)
 09.30-10.15 BHIVA Guidelines / Commissioning Update (45 mins)

Speaker: Dr Laura Waters, GUM/HIV Consultant and HIV and Hepatitis Lead – The Mortimer Market Centre, Central and North West London NHS Foundation Trust.

Key objectives:

To be aware of the changes in the 2022 BHIVA treatment guideline and NHSE ARV commissioning policy.

To understand the evidence base supporting key treatment recommendations for people living with HIV.

To describe the place of injectable ART in the care of people living with HIV in the UK.

10.15-10.45 Industry update: ViiV (30 mins)

Speaker: TBC

10.45-11.00 **Coffee break** (15 mins)

11.00-11.30 Peer support and the impact of COVID-19 on the care of people living with HIV (30 min)

Speaker: Susan Cole, Community Engagement, Marketing and Membership Manager - NAM

Key objectives:

To gain an insight into the impact of the COVID-19 pandemic on HIV care from the perspective of people living with HIV.

To understand people living with HIV's experience of telemedicine during the COVID-19 pandemic.

To describe the unmet care needs of people living with HIV in the post COVID era.

11.30-12.30 Industry update: Gilead (60 mins)

Speaker: Dr Mark Lawton & Breda Patterson

Title: HIV drug resistance development, viral fitness and resistance testing

12.30-13.20 **Lunch** (50 mins)

### **HIVPA Conference 2022 Agenda**

#### 13.20-13.50 **Industry update: MSD** (30 mins)

Speaker: Stephanie Tyler, Highly Specialist Pharmacist – HIV, Sexual and Reproductive Health - Guy's & St. Thomas' NHS Foundation Trust

Title: "HIV and Metabolic Disorders. What we know...to switch or not to switch?"

#### 13.50-14.35 **Pregnancy Update** (45 mins)

Speaker: Professor Yvonne Gilleece, Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health – Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust

#### Key objectives:

Describe the current guidelines for pregnant women living with HIV.

Discuss the data and evidence for breast-feeding mothers living with HIV.

To describe the uncertainties of managing late HIV diagnoses in pregnancy.

#### 14.35-15.05 **Complex Cases / Virtual Clinic** (30 mins)

Speakers: TBC Key objectives:

To learn from the experience of peers who have managed patients with complex care needs requiring individualized antiretroviral treatment.

To apply the latest learning from the BHIVA treatment guidelines to the care of patients living with HIV with multiple co-morbidities and extensive past antiretroviral use.

#### 15.05-15.20 **Coffee break** (15 mins)

#### 15.20-16.50 Advanced Practice / Pharmacist Experience (90 mins)

Speakers:

Hasan Mohammed, Advanced Pharmacist Practitioner – Chelsea & Westminster Hospital NHS Foundation Trust Heather Leake Date, Consultant Pharmacist HIV/Sexual Health – University Hospitals Sussex NHS Foundation Trust. Honorary Senior Lecturer, University of Brighton. Clinical member and Drugs Subgroup Co-chair, NHS England HIV Clinical Reference Group

Stephanie Tyler, Highly Specialist Pharmacist, HIV, Sexual and Reproductive Health - Guy's & St. Thomas' NHS Foundation Trust

Yemi Daramola, Highly Specialist Pharmacist HIV/GUM - Inpatient & Daycare Lead - Chelsea & Westminster Hospital NHS Foundation Trust

#### Key objectives:

To be aware of opportunities for HIV/GUM pharmacists in advanced practice roles.

To describe the skills, qualities and experience required to pursue an advanced practice role.

To gain an insight into the challenges and rewards associated with working in an advanced practice role.

#### 16.50-17.35 **RPS / Faculty / Advanced Practice** (45 mins)

Speakers:

Lucy Hedley Senior Procurement Pharmacist Pharmacy Procurement & Homecare - The Newcastle upon Tyne Hospitals NHS Foundation Trust

RPS representative TBC

Key objectives:

To be aware how the RPS can support pharmacists with their professional development.

To understand the differences between the RPS Faculty and RPS Core Advanced and Consultant credentialing.

To gain an insight into the e-portfolio requirements and assessment process for the RPS Faculty and RPS Core Advance and Consultant credentialing.

### **Dates For Your Diary**



### **HIVPA Annual Conference**

London, 3rd September 2022

https://hivpa.org/hivpa-conference-2021/

# International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Barcelona & Virtual, 19th—22nd September 2022

https://academicmedicaleducation.com/meeting/clinical-pharmacology-2022

### Nurses & Pharmacists HIV Clinical Forum 2022

London, 30th September 2022

https://academicmedicaleducation.com/meeting/nurses-pharmacists-2022

### **Dates For Your Diary**

### DDI Management in HIV Care | The Liverpool Course

Virtual, 28th September 2022

https://academicmedicaleducation.com/meeting/liverpool-course-2022

### **ID Week 2022**

Washington, DC, 19th October - 23rd October 2022 <a href="https://idweek.org/">https://idweek.org/</a>

### **HIV Drug Therapy Glasgow 2022**

Glasgow & Virtual, 23rd October - 26th October 2022 <a href="http://hivglasgow.org/">http://hivglasgow.org/</a>

### **BHIVA Autumn Conference 2022**

London, 25th November 2022

https://www.bhiva.org/AutumnConference2022

### Real world data of people living with HIV-2

# Real world data of people living with HIV-2: experience of 7 London clinics

Stephanie Tyler<sup>1</sup>, Sarah Keegan<sup>1</sup>, Chon Lam<sup>2</sup>, Yemi Daramola<sup>3</sup>, Nadine Collins<sup>4</sup>, Abhishek Katiyar<sup>5</sup>, Donna Johnson<sup>6</sup>, Carol Jones<sup>7</sup>, Poonam Ranchan<sup>7</sup>, Ranjana Jayaprakash<sup>7</sup>, Ranjababu Kulasegaram<sup>1</sup>

<sup>1</sup>Guy's and St Thomas' NHS Foundation Trust, <sup>2</sup>St George's Hospital, <sup>3</sup>Chelsea and Westminster Hospital, <sup>4</sup>Lewisham and Greenwich Hospital, <sup>5</sup>Bound From Hospital, <sup>6</sup>Founday Hoalth Spatian Trust, <sup>7</sup>Backing, Hawking and Badhridge University Hospital, NHS Trust

### Background

- HIV-2 is mainly restricted to West Africa, estimated around 1-2 million people worldwide. HIV-2 prevalence is low in the UK forming the minority of people living with HIV (PLWH).
- To date, there have been no published RCTs of ART for HIV-2. Most guidelines have been developed from evidence based on cohort and observational studies.
- Certain ART do not have activity against HIV-2 and clinical impression is that there is much variation in prescribing.
- We aim to describe ART choices and virological outcomes.

### Method


- A retrospective observational study was conducted using electronic medical records of all PLWH-2 and/or co-infected with HIV-1.
- A data collection tool was piloted and a collaboration was established at the HIV Pharmacist London Leads meeting.
- The target population was all PLWH who have HIV-2 +/- co-infected with HIV-1 who have attended one of the 7 London Clinics.

### Results

- 67 PLWH-2 were identified. The demographics included 60% female, 85% black ethnicity, 73% heterosexual exposure risk, median age of 56 years and a mean of 10 years living with HIV.
- 56 (84%) are on ART and of those 38 (68%) are undetectable.
- Only 16 (24%) people had a baseline resistance test available on file.
- Of those on ART; 37 (66%) were on a PI or 2<sup>nd</sup> generation integrase inhibitor.
- 9 people were treatment naïve and of those 88% remain undetectable.
- The mean CD4 count was 499 with 31% having a CD4<350.</li>

	HIV-2 HIV-1 co-infected Total			
	(n=55)	(n=12)	(n=67)	
HIV diagnosis date:				
- 1980-1990	1	•	1	
- 1991-2000	3	5	8	
- 2001-2010	18	7	25	
- 2011- 2021	32	-	32	
- Not known	1	-	1	
N. of years living with HIV-2 (mean)	9	12	10	
Sex, n (%)	M:21 (38%)	M:6 (50%)	M: 27 (40%)	
	F:34 (62%)	F:6 (50%)	F:40 (60%)	
Median age, years	55	59	56	
Ethnicity				
Black - Caribbean, African, British, other	45	12	57	
White - British, Irish, other	2	-	2	
Mixed – White and Black African, White and Asian, other	1	-	1	
Other	4	-	4	
Not known	3	-	3	
Exposure				
Sexual exposure (Heterosexual)	38	11	49	
Sexual exposure (MSM)	1	1	2	
Blood transfusion	1		1	
Exposure risk contact with blood products	1		1	
Unknown	14	-	14	
Nadir CD4 (mean)	335	296	327	
Most recent CD4 (mean)	495	518	499	
Baseline CD8 (mean)	543	957	629	
Most recent CD4/CD8 ratio (mean)	0.99	0.68	0.94	

	HIV-2 (n=55)	HIV-1 co-infected (n=12)	Total (n=67)
On ART Treatment naïve Off treatment Unknown	47 8 -	9 1 1	56 9 1 1
Mean time on ART (years)	6	12	6
Mean number of ART switches	2	3	2
Current ART  2NRTI + PI (OD)  2NRTI + 2 <sup>nd</sup> gen INSTI (BIC or DTG)  2NRTI + RAL  ART containing BD DRV/RTV  Alternative ART	16 15 3 5	4 2 - - 3	20 17 3 5




#### Conclusion

- The majority of PLWH-2 are on treatment (84%) with a high genetic barrier regimen (66%). Of those on ART 68% are undetectable.
- The majority (76%) did not have any baseline resistance testing available. Of the 9 PLWH-2 who are treatment naïve 88% remain undetectable.
- The findings are limited by small numbers and missing data.
- The results show that in this cohort the UNAIDs 90 90 90 target has not been met. To help meet the goal of ending the AIDS pandemic by 2030, new
  attention must be given to this neglected HIV cohort.
- With the recent publication of the BHIVA HIV-2 guideline our aim is to look at current prescribing and outcomes again in 1 year.

### **Empowering Students: End HIV Stigma**

### **New HIV education toolkit**

## **Empower Students: End HIV Stigma**



### **Empowering Students: End HIV Stigma**

# New education toolkit to empower students to become the generation that ends HIV stigma

A new toolkit developed by young people living with HIV will enable teachers to educate young people with the facts about HIV in an engaging way and inspire them to become the generation that ends HIV stigma.

The new resource called 'Empowering Students: End HIV Stigma' was officially launched at an event at Parliament on 23 March 2022, organised by UK charity CHIVA and hosted by the All-Party Parliamentary Group on HIV and AIDS.

Young people growing up with HIV in the UK face a number of challenges. Many of the young people who use CHIVA services describe experiences where they have heard inaccurate information about HIV in schools, such as misinformation about how HIV can be transmitted from one person to another.

Young people living with HIV can feel powerless in these situations and are fearful to speak out because of the discrimination they may face. People often experience stigma or discrimination if they are living with HIV, and this is often based on myths and stereotypes.

The CHIVA Youth Committee (children and young people living with HIV) worked with trainer and facilitator, Camilla Gordon, to develop the education toolkit which is to be used in lessons alongside a screening of CHIVA's award-winning short film, *Life Growing Up*. The film provides insights into the lived experiences of young people growing up with HIV in the UK.

All secondary schools in England are required to be delivering the Relationships and Sex Education guidance which was implemented in September 2021, and HIV should be included in that. The new toolkit is designed for key stages 3 and 4 and helps

teachers to fulfil that requirement. The resource could also be useful for older age groups and wider education settings.

CHIVA has also worked in collaboration with the National Children's Bureau to update the *HIV in Schools* guidance, which provides information for teachers and schools to ensure that a pupil who shares information about their HIV diagnosis will receive the appropriate support whilst confidentiality is respected.

Florence Eshalomi MP for Vauxhall, Co-Chair of the All-Party Parliamentary Group HIV and AIDS said, "Schools who follow this guidance will be well equipped to support any children living with HIV. This alongside CHIVA's education toolkit, will provide schools with the ideal package of resources to empower a generation of teachers and students with the knowledge needed to end HIV stigma. This fully aligns with the APPG's aims to ensure that all people living with HIV have a good quality of life, free from stigma, discrimination and fear."

The new toolkit and updated guidance can be found at: www.chiva.org.uk/education

Watch *Life Growing Up* at: <a href="www.chiva.org.uk/">www.chiva.org.uk/</a> lifegrowingup



























Find Your Four is a campaign developed and funded by Gilead Sciences, in collaboration with the HIV community.